Atea Pharmaceuticals Inc (AVIR) Stock Price, Quote & News

Company Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 284 8891

Website: ateapharma.com

Address:

225 Franklin Street, Suite 2100, Boston, United States

VictorRamos508 Feb. 21 at 8:41 AM

$AVIR Atea Pharmaceuticals develops antiviral therapies. Clinical execution drives valuation. Early-stage risk remains high.

0 · Reply

Following_the_trend Feb. 20 at 2:57 PM

$AVIR Steady mover

0 · Reply

Barkingdogs Feb. 17 at 9:45 PM

$AVIR why's this one going up steadily being accumulated paying up

0 · Reply

Bren10OD Feb. 17 at 8:35 PM

$AVIR what’s happening here?

0 · Reply

OfficialStocktwitsUser Feb. 13 at 7:16 PM

$AVIR RSI: 60.68, MACD: 0.2087 Vol: 0.29, MA20: 4.00, MA50: 3.61 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Cocky_day_trader Feb. 11 at 6:36 PM

$AVIR finally we are green Lets go

0 · Reply

Bren10OD Feb. 11 at 5:18 PM

$AVIR what’s happening here?

0 · Reply

Chrissytina Feb. 2 at 7:24 PM

$AVIR I really wanted to be happy it was up…but I knew better 🤦🏼‍♀️

0 · Reply

Cocky_day_trader Feb. 2 at 12:09 AM

$AVIR following and processing

0 · Reply

OnlyFibs Jan. 31 at 9:26 PM

$AVIR is a textbook breakout! 🧬📈 Reclaiming $4.14 as support is the massive pivot bulls have been waiting for. With a fresh Golden Cross and Phase 3 HCV data looming in mid-2026, the $301M cash cushion makes this a high-conviction "safety" play in biotech. 🛡️🚀 🐂 Bulls: Must hold $4.14 and clear $4.34 (52-week high) to target $6.12. 🐻 Bears: Looking for a break below $3.80 to invalidate the breakout. Confirming level: $4.34 #AVIR #Biotech #AteaPharma #GoldenCross #hovdid

1 · Reply

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Jan 15, 2026, 1:55 PM EST - 5 weeks ago

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 8, 2026, 7:00 AM EST - 6 weeks ago

Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:00 AM EST - 7 weeks ago

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 23, 2025, 5:51 AM EST - 2 months ago

Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026

Dec 22, 2025, 7:00 AM EST - 2 months ago

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Nov 19, 2025, 7:00 AM EST - 3 months ago

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

Nov 13, 2025, 2:31 PM EST - 3 months ago

Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript

Nov 12, 2025, 7:01 PM EST - 3 months ago

Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:05 PM EST - 3 months ago

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 8:00 AM EST - 3 months ago

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Nov 5, 2025, 7:00 AM EST - 4 months ago

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

Oct 22, 2025, 7:00 AM EDT - 4 months ago

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025

Oct 7, 2025, 8:00 AM EDT - 5 months ago

Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Sep 9, 2025, 5:51 PM EDT - 6 months ago

Atea Pharmaceuticals, Inc. (AVIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 7:00 AM EDT - 6 months ago

Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 8, 2025, 3:29 PM EDT - 7 months ago

Atea Pharmaceuticals, Inc. (AVIR) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:00 AM EDT - 7 months ago

Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025

Jun 24, 2025, 7:00 AM EDT - 8 months ago

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

May 12, 2025, 4:11 PM EDT - 10 months ago

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 7:00 AM EDT - 10 months ago

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

May 1, 2025, 7:00 AM EDT - 10 months ago

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

Apr 23, 2025, 7:00 AM EDT - 11 months ago

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

Apr 17, 2025, 7:00 AM EDT - 11 months ago

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

Apr 9, 2025, 7:00 AM EDT - 11 months ago

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Mar 31, 2025, 7:04 PM EDT - 11 months ago

Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination

Mar 26, 2025, 1:58 PM EDT - 11 months ago

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

Mar 26, 2025, 8:00 AM EDT - 1 year ago

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Mar 21, 2025, 5:54 PM EDT - 1 year ago

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

Mar 19, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

Mar 6, 2025, 6:14 PM EST - 1 year ago

Atea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

Feb 24, 2025, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

Jan 8, 2025, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 5:05 PM EST - 1 year ago

Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

Dec 16, 2024, 5:00 AM EST - 1 year ago

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

Dec 4, 2024, 3:14 PM EST - 1 year ago

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

Dec 4, 2024, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

Nov 26, 2024, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

Nov 15, 2024, 11:00 AM EST - 1 year ago

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Nov 9, 2024, 1:14 PM EST - 1 year ago

Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway

Aug 11, 2024, 12:13 PM EDT - 1 year ago

Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024

May 29, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

VictorRamos508 Feb. 21 at 8:41 AM

$AVIR Atea Pharmaceuticals develops antiviral therapies. Clinical execution drives valuation. Early-stage risk remains high.

0 · Reply

Following_the_trend Feb. 20 at 2:57 PM

$AVIR Steady mover

0 · Reply

Barkingdogs Feb. 17 at 9:45 PM

$AVIR why's this one going up steadily being accumulated paying up

0 · Reply

Bren10OD Feb. 17 at 8:35 PM

$AVIR what’s happening here?

0 · Reply

OfficialStocktwitsUser Feb. 13 at 7:16 PM

0 · Reply

Cocky_day_trader Feb. 11 at 6:36 PM

$AVIR finally we are green Lets go

0 · Reply

Bren10OD Feb. 11 at 5:18 PM

$AVIR what’s happening here?

0 · Reply

Chrissytina Feb. 2 at 7:24 PM

$AVIR I really wanted to be happy it was up…but I knew better 🤦🏼‍♀️

0 · Reply

Cocky_day_trader Feb. 2 at 12:09 AM

$AVIR following and processing

0 · Reply

OnlyFibs Jan. 31 at 9:26 PM

1 · Reply

StockScanners Jan. 31 at 9:19 AM

$AVIR keep watch if this holds above 4.10

0 · Reply

StockScanners Jan. 27 at 3:36 AM

$AVIR reached 4.01

0 · Reply

OfficialStocktwitsUser Jan. 26 at 10:48 PM

$AVIR RSI: 68.10, MACD: 0.1360 Vol: 0.19, MA20: 3.57, MA50: 3.31 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply